[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

PURPOSE: Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Evelyn E. C., van Elmpt, Wouter, Leijenaar, Ralph T. H., Hoekstra, Otto S., Groen, Harry J. M., Smit, Egbert F., Boellaard, Ronald, van der Noort, Vincent, Troost, Esther G. C., Lambin, Philippe, Dingemans, Anne-Marie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121177/
https://www.ncbi.nlm.nih.gov/pubmed/27600280
http://dx.doi.org/10.1007/s00259-016-3498-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121177/
https://www.ncbi.nlm.nih.gov/pubmed/27600280
http://dx.doi.org/10.1007/s00259-016-3498-y

Ejemplares similares